• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24338 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (giant cell arteritis) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glofitamab (DLBCL, monotherapy, third line or later) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glofitamab (DLBCL, combination with gemcitabine and oxaliplatin) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (oesophageal squamous cell carcinoma, first line) – Benefit assessment according to §35a Social Code Book V]
2025     Health Information and Quality Authority (HIQA) Paediatric early warning systems in emergency settings: protocol for a systematic review of clinical guidelines
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Initiating a diagnostic and therapeutic measure in a person with signs and symptoms of pharyngitis/tonsillitis]
2025     NIHR Health Technology Assessment programme Developing evidence-based guidelines for describing potential benefits and harms within patient information leaflets/sheets (PILs) that inform and do not cause harm (PrinciPILs)
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Fluoroscopic or endoscopic evaluation of dysphagia in adults]
2025     NIHR Health and Social Care Delivery Program Meeting the needs of women in the perinatal period, who use or are in treatment for using drugs: a mixed-methods systematic review
2025     NIHR Health Technology Assessment programme Eradication of Helicobacter pylori for prevention of aspirin-associated peptic ulcer bleeding in adults over 65 years: the HEAT RCT
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Best group interventions for perpetrators of intimate partner violence]
2025     Austrian Institute for Health Technology Assessment (AIHTA) Temporary nitinol implantation for the treatment of benign prostatic hyperplasia
2025     Austrian Institute for Health Technology Assessment (AIHTA) Leadless cardiac pacemakers
2025     Austrian Institute for Health Technology Assessment (AIHTA) One-stage matrix-assisted cartilage repair with and without bone marrow aspirate concentrate in the knee
2025     Austrian Institute for Health Technology Assessment (AIHTA) Thermal ablation for early-stage breast cancer: cryoablation, microwave, radiofrequency, high-intensity focused ultrasound, and laser ablation
2025     Austrian Institute for Health Technology Assessment (AIHTA) Drug-coated balloon catheter for the treatment of urethral strictures
2025     Austrian Institute for Health Technology Assessment (AIHTA) Islet cell transplantation for chronic pancreatitis, type 1 diabetes, with and without kidney transplantation
2025     NIHR Health Technology Assessment programme Determining optimal strategies for primary prevention of cardiovascular disease: a synopsis of an evidence synthesis study
2025     NIHR Health Technology Assessment programme Glycaemic control in labour with diabetes: GILD, a scoping study
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of percutaneous nephrolithotomy, flexible ureterorenoscopy and extracorporeal shockwave lithotripsy for lower pole stones: the PUrE RCTs
2025     NIHR Health Technology Assessment programme Optimising cardiac surgery outcomes in people with diabetes: the OCTOPuS pilot feasibility study
2025     NIHR Health Technology Assessment programme Medical management and intervention (using neurosurgical resection or stereotactic radiosurgery) versus medical management alone for symptomatic brain cavernoma: the CARE pilot RCT
2025     NIHR Health Technology Assessment programme OrthoticS for TReatment of symptomatic flat feet In CHildren (OSTRICH): a randomised controlled trial
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Diabetic foot infection in adults: optimal use of antibiotic therapy and measures to prevent recurrence]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [In-toto thrombectomy using a retriever/aspiration system for acute pulmonary artery embolism]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a transcatheter tricuspid valve replacement for tricuspid valve insufficiency – 3rd Addendum to Project H23-03]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Normothermic organ preservation with functional monitoring in liver transplantation - Assessment according to §137h Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sipavibart (pre exposure prophylaxis of COVID 19) – 2nd Addendum to Project A25-28]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Serplulimab (small cell lung cancer, first line) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tiratricol (Allan-Herndon-Dudley syndrome) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Iptacopan (complement 3 glomerulopathy) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sipavibart (pre exposure prophylaxis of COVID 19) – Addendum to Project A25-28]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sarilumab (polymyalgia rheumatica) – Addendum to Project A25-18]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, ≥ 2 years, at least 1 non-class I mutation, including gating mutation, excluding F508del mutation) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, ≥ 2 years, at least one non-class I mutation, excluding F508del and gating mutations) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elosulfase alfa (mucopolysaccharidosis IVA) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Repotrectinib (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Repotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bevacizumab gamma (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (pleural mesothelioma) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eplontersen (hereditary transthyretin amyloidosis with polyneuropathy) – Benefit assessment according to §35a Social Code]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pirtobrutinib (CLL) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisocabtagene maraleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer, pMMR) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection – epcoritamab (DLBCL)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection – loncastuximab (DLBCL)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for odronextamab (DLBCL) - First addendum to Project A24-18]
2025     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Suvanto Care Safety Service
2025     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Orla INR Remote Monitoring
2025     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Zoturi — Online Story-Based Support for youth and families
2025     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Sotender application for allocating social services and health care gig work
2025     Austrian Institute for Health Technology Assessment (AIHTA) Trauma care: teaching recovery technique (TRT) to children and adolescent refugees. Systematic review and evaluation of Austrian TRT-Programme at AFYA
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Microinvasive surgical (MIGS) devices and procedures for the treatment of moderate to severe glaucoma]
2025     Austrian Institute for Health Technology Assessment (AIHTA) CAR-T cell therapy: updated effectiveness and safety results from real-world evidence: a systematic review
2025     Austrian Institute for Health Technology Assessment (AIHTA) [Telerehabilitation for movement support in people with chronic back pain – rapid review of effectiveness]
2025     NIHR Health Services and Delivery Research programme Implementation of link workers in primary care: synopsis of findings from a realist evaluation
2025     NIHR Health Technology Assessment programme Extracorporeal carbon dioxide removal for the treatment of acute hypoxaemic respiratory failure: the REST RCT
2025     Austrian Institute for Health Technology Assessment (AIHTA) Teprotumumab (TEPEZZA®) for moderate-to-severe thyroid eye disease
2025     NIHR Health Technology Assessment programme BioImpedance Spectroscopy to maintain Renal Output: the BISTRO randomised controlled trial
2025     Austrian Institute for Health Technology Assessment (AIHTA) [Serum eye drops for patients with severe ocular surface disease]
2025     Austrian Institute for Health Technology Assessment (AIHTA) Fidanacogene elaparvovec (BEQVEZ®) for the treatment of moderately severe to severe haemophilia B
2025     NIHR Health Technology Assessment programme Methylphenidate versus placebo for fatigue in patients with advanced cancer: the MePFAC randomised controlled trial
2025     NIHR Health Technology Assessment programme Outcomes of specialist physiotherapy for functional motor disorder: the Physio4FMD RCT
2025     NIHR Health Services and Delivery Research programme A digital intervention to improve mental health and interpersonal resilience for young people who have experienced online sexual abuse: the i-Minds non-randomised feasibility clinical trial and nested qualitative study
2025     NIHR Health Services and Delivery Research programme Evaluation of the NHS England Low-Calorie Diet implementation pilot: a coproduced mixed-method study
2025     NIHR Health Technology Assessment programme Cessation of smoking in people attending UK emergency departments: the COSTED RCT with economic and process evaluation
2025     NIHR Health Services and Delivery Research programme Centralisation of specialised healthcare services: a scoping review of definitions, types, and impact on outcomes
2025     National Institute for Health and Care Excellence (NICE) Pulsed–field ablation for atrial fibrillation. NICE interventional procedures guidance 806
2025     National Institute for Health and Care Excellence (NICE) Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over. NICE technology appraisal guidance 1077
2025     National Institute for Health and Care Excellence (NICE) Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 1076
2025     National Institute for Health and Care Excellence (NICE) Dapagliflozin for treating chronic kidney disease. NICE technology appraisal guidance 1075
2025     National Institute for Health and Care Excellence (NICE) Mirikizumab for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 1080
2025     National Institute for Health and Care Excellence (NICE) Zanubrutinib for treating relapsed or refractory mantle cell lymphoma. NICE technology appraisal guidance 1081
2025     National Institute for Health and Care Excellence (NICE) Fruquintinib for previously treated metastatic colorectal cancer. NICE technology appraisal guidance 1079
2025     National Institute for Health and Care Excellence (NICE) Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal). NICE technology appraisal guidance 1084
2025     National Institute for Health and Care Excellence (NICE) Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal). NICE technology appraisal guidance 1083
2025     National Institute for Health and Care Excellence (NICE) Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal). NICE technology appraisal guidance 1082
2025     National Institute for Health and Care Excellence (NICE) Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over. NICE technology appraisal guidance 1085
2025     Health Sciences Institute in Aragon (IACS) [In vitro method for the diagnosis and/or prognosis of multiple sclerosis]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Multi-gene expression profiling tests to assess recurrence risk in early-stage breast cancer patients]
2025     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the clinical safety and comparative efficacy and effectiveness of autologous skin grafts of the skin graft type in patients with difficult to heal wounds]
2025     NIHR Health Technology Assessment programme Feasibility, acceptability and appropriateness of laparoscopic versus abdominal hysterectomy for women and healthcare professionals: the LAVA trial qualitative process evaluation
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Idiopathic scoliosis: digital solutions for detection, diagnosis, and monitoring in children and adolescents]
2025     Health Information and Quality Authority (HIQA) Retiring a clinical guideline: rapid scoping review
2025     Health Information and Quality Authority (HIQA) Draft health technology assessment of extending BowelScreen to those aged 50 to 54 years
2025     Health Information and Quality Authority (HIQA) Magnetic resonance-guided radiotherapy (MRgRT) evidence synthesis to support a generic justification decision
2025     Canary Health Service [Repetitive transcranial magnetic stimulation for psychiatric and neurologic disorders]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Polymalformative syndromes next-generation sequencing (NGS) panel – repatriation of an analysis carried out outside of the province of Québec]
2025     Regione Emilia Romagna (RER) [Tumour treating fields (TTFields) for the treatment of patients with newly diagnosed and recurrent glioblastoma]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Scientific paper on the methods for routine practice data collection for the purpose of assessing the benefits of drugs in accordance with §35a of the German Social Code Book V (SGB V)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Percutaneously implanted interatrial shunt for the treatment of heart failure with reduced left ventricular ejection fraction (LVEF < 40 %)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Test quality: Evidence report for the S3 guideline on allergic rhinitis]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [House dust mites: Evidence report for the S3 guideline on allergic rhinitis]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pollen: Evidence report for the S3 guideline on allergic rhinitis]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pets-rodents: Evidence report for the S3 guideline on allergic rhinitis]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Flour: Evidence report for the S3 guideline on allergic rhinitis]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Laboratory animals – farm animals: Evidence report for the S3 guideline on allergic rhinitis]